Beta-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease



Status:Recruiting
Conditions:Chronic Obstructive Pulmonary Disease, Pulmonary
Therapuetic Areas:Pulmonary / Respiratory Diseases
Healthy:No
Age Range:40 - 84
Updated:6/2/2018
Start Date:May 2016
End Date:May 2020
Contact:Mark Dransfield, MD
Email:mdrans99@uab.edu

Use our guide to learn which trials are right for you!

Beta-Blockers for the Prevention of Acute Exacerbations of COPD

This is a multicenter, prospective, randomized, double-blind, placebo-controlled trial that
will enroll 1028 patients with at least moderately severe COPD over a three year period and
follow them at regular intervals for one year. The primary endpoint is time to first acute
exacerbation. Secondary endpoints include rates and severity of COPD exacerbations,
cardiovascular events, all-cause mortality, lung function, dyspnea, quality of life and
metoprolol-related side effects.

Hypothesis The primary hypothesis is that metoprolol succinate will reduce the risk of COPD
exacerbations as compared to placebo. The secondary hypothesis is that metoprolol succinate
will not adversely impact lung function, exercise tolerance, dyspnea or quality of life as
compared to placebo.

Study Flow Patients will be screened and then randomized over a 2 week period and will then
undergo a dose titration period for the following six weeks. Thereafter patients will be
followed for 42 additional weeks on their target dose of metoprolol or placebo followed by a
4 week washout period.

Specific Aims:

Primary: To determine the effect of once daily metoprolol succinate compared with placebo on
the time to first exacerbation in moderate to severe COPD patients who are prone to
exacerbations and who do not have absolute indications for beta-blocker therapy.

Secondary: To estimate the effect of metoprolol succinate compared with placebo on:

1. The rate and severity of COPD exacerbations over 12 months

2. Incidence and severity of metoprolol-related side effects including those that require
cessation of drug

3. Lung function as assessed by spirometry, dyspnea as assessed by the Modified Medical
Research Council Scale (MMRC) and San Diego Shortness of Breath Questionnaire, exercise
tolerance as measured by six minute walk test (6MWD), and quality of life as assessed by
the Short Form 36, St. Georges Respiratory Questionnaire (SGRQ) and COPD Assessment Test
(CAT) and Personal HEART Score.

4. Hospitalizations

5. The rate of major adverse cardiovascular events (MACE) (defined by cardiovascular death,
hospitalization for myocardial infarction, heart failure, or stroke), percutaneous
coronary intervention or coronary artery bypass grafting

6. All-cause mortality

Secondary subgroup analyses for 1) cardiovascular risk based on Personal HEART Score and 2)
age greater versus less than 65.

Inclusion Criteria:

1. Male and female subjects, ≥ 40 and less than 85 years of age

2. Clinical diagnosis of at least moderate COPD as defined by the Global Initiative for
Obstructive Lung Disease (GOLD) criteria (53):

- Post bronchodilator FEV1/FVC < 70% (Forced expiratory volume in 1 second/ forced
vital capacity),

- Post bronchodilator FEV1 < 80% predicted, with or without chronic symptoms (i.e.,
cough, sputum production).

3. Cigarette consumption of 10 pack-years or more. Patients may or may not be active
smokers.

4. To enrich the population for patients who are more likely to have acute exacerbations
(54), each subject must meet one or more of the following 4 conditions:

- Have a history of receiving a course of systemic corticosteroids and/or
antibiotics for respiratory problems in the past year,

- Visiting an Emergency Department for a COPD exacerbation within the past year, or

- Being hospitalized for a COPD exacerbation within the past year

- Be using or be prescribed supplemental oxygen for 12 or more hours per day

- Willingness to make return visits and availability by telephone for duration of
study.

Exclusion Criteria:

1. A diagnosis of asthma established by each study investigator on the basis of the
recent American Thoracic Society/European Respiratory Society and National Institute
for Health and Care Excellence guidelines.

2. The presence of a diagnosis other than COPD that results in the patient being either
medically unstable, or having a predicted life expectancy < 2 years.

3. Women who are at risk of becoming pregnant during the study (pre-menopausal) and who
refuse to use acceptable birth control (hormone-based oral or barrier contraceptive)
for the duration of the study.

4. Current tachy or brady arrhythmias requiring treatment

5. Presence of a pacemaker and/or internal cardioverter/defibrillator

6. Patients with a history of second or third degree (complete) heart block, or sick
sinus syndrome

7. Baseline EKG revealing left bundle branch block, bifascicular block, ventricular
tachyarrhythmia, atrial fibrillation, atrial flutter, supraventricular tachycardia
(other than sinus tachycardia and multifocal atrial tachycardia), or heart block (2nd
degree or complete)

8. Resting heart rate less than 65 beats per minute, or sustained resting tachycardia
defined as heart rate greater than 120 beats per minute.

9. Resting systolic blood pressure of less than 100mm Hg.

10. Subjects with absolute (Class 1) indications for beta-blocker treatment as defined by
the combined American College of Cardiology Foundation/American Heart Association Task
Force on Practice Guidelines, and the American College of Physicians, American
Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association,
Society for Cardiovascular Angiography and Interventions, and Society of Thoracic
Surgeons Guidelines which include myocardial infarction, acute coronary syndrome,
percutaneous coronary intervention or coronary artery bypass surgery within the prior
3 years and patients with known congestive heart failure defined as left ventricular
ejection fraction <40%.(29, 30)

11. Critical ischemia related to peripheral arterial disease.

12. Other diseases that are known to be triggered by beta-blockers or beta-blocker
withdrawal including myasthenia gravis, periodic hypokalemic paralysis,
pheochromocytoma, and thyrotoxicosis

13. Patients on other cardiac medications known to cause atrioventricular (AV) node
conduction delays such as amiodarone, digoxin, and calcium channel blockers including
verapamil and diltiazem as well as patients taking clonidine.

14. Hospitalization for uncontrolled diabetes mellitus or hypoglycemia within the last 12
months.

15. Patients with cirrhosis

16. A clinical diagnosis of bronchiectasis defined as production of > one-half cup of
purulent sputum/day.

17. Patients otherwise meeting the inclusion criteria will not be enrolled until they are
a minimum of four weeks from their most recent acute exacerbation (i.e., they will not
have received a course of systemic corticosteroids, an increased dose of chronically
administered systemic corticosteroids, and/or antibiotics for an acute exacerbation
for a minimum of four weeks).
We found this trial at
27
sites
Denver, Colorado 80206
Principal Investigator: Barry Make, MD
Phone: 303-398-1518
?
mi
from
Denver, CO
Click here to add this to my saved trials
621 West Lombard Street
Baltimore, Maryland 21201
(410) 706-7101
Principal Investigator: Robert Reed, MD
Phone: 410-328-4155
University of Maryland, Baltimore Welcome to the University of Maryland, Baltimore (UMB) founded in 1807...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
1720 2nd Ave S
Birmingham, Alabama 35233
(205) 934-4011 
Principal Investigator: Mark Dransfield, MD
Phone: 205-934-9282
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
75 Francis street
Boston, Massachusetts 02115
(617) 732-5500
Principal Investigator: Carolyn Come
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
?
mi
from
Boston, MA
Click here to add this to my saved trials
85 S Prospect St
Burlington, Vermont 5405
(802) 656-3131
Principal Investigator: David Kaminsky, MD
Phone: 802-847-2193
University of Vermont The University of Vermont combines faculty-student relationships most commonly found in a...
?
mi
from
Burlington, VT
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
216.444.2200
Principal Investigator: Umur Hatipoglu, M.D.
Phone: 216-444-1150
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Gainesville, Florida 32608
Principal Investigator: Peruvemba Sriram, MD
Phone: 352-548-6000
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
116th St and Broadway
New York, New York 10027
(212) 854-1754
Principal Investigator: Keith Brenner, MD
Phone: 212-746-4377
Columbia University In 1897, the university moved from Forty-ninth Street and Madison Avenue, where it...
?
mi
from
New York, NY
Click here to add this to my saved trials
4200 Fifth Ave
Pittsburgh, Pennsylvania 15260
(412) 624-4141
Principal Investigator: Frank Sciurba, MD
Phone: 412-383-1607
University of Pittsburgh The University of Pittsburgh is a state-related research university, founded as the...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Ann Arbor, Michigan 48113
Principal Investigator: Jeffery Curtis, MD
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
500 S State St
Ann Arbor, Michigan 48109
(734) 764-1817
Principal Investigator: MeiLan Han, MD MS
University of Michigan The University of Michigan was founded in 1817 as one of the...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Birmingham, Alabama 35233
Principal Investigator: Allen Cooper, MD
Phone: 205-933-2182
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Brooklyn, New York 11215
Principal Investigator: Jeremy Weingarten, MD
Phone: 718-780-5906
?
mi
from
Brooklyn, NY
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Principal Investigator: Ravi Kalhan, MD
Phone: 312-926-4533
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Cincinnati, Ohio 45220
Principal Investigator: Ralph Panos, MD
Phone: 513-861-3100
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Flushing, New York 11355
Principal Investigator: Anthony Smith, MD
Phone: 718-670-2414
?
mi
from
Flushing, NY
Click here to add this to my saved trials
Fresno, California
Principal Investigator: Vipul Jain, MD, MS
Phone: 559-499-6677
?
mi
from
Fresno, CA
Click here to add this to my saved trials
Ithaca, New York 14853
Principal Investigator: Robert Kaner, MD
Phone: 212-746-4377
?
mi
from
Ithaca, NY
Click here to add this to my saved trials
Los Angeles, California 90502
Principal Investigator: William Stringer, MD
Phone: 310-974-9567
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Minneapolis, Minnesota 55417
Principal Investigator: Dennis Niewoehner, MD
Phone: 612-467-5279
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Minneapolis, Minnesota 55440
Principal Investigator: Charlene McEvoy, MD, MPH
Phone: 952-967-5084
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
New Orleans, Louisiana 70112
Principal Investigator: Matthew Lammi, MD, MSCR
Phone: 504-568-3452
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19140
Principal Investigator: Gerard Criner, MD
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Rochester, Minnesota 55905
Principal Investigator: Paul Scanlon, MD
Phone: 507-284-9946
?
mi
from
Rochester, MN
Click here to add this to my saved trials
Salt Lake City, Utah 84132
Principal Investigator: Richard E Kanner, MD
Phone: 801-581-6496
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
San Francisco, California 94143
Principal Investigator: Stephen C. Lazarus, MD
Phone: 415-502-1852
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
Spokane, Washington 99258
Principal Investigator: Allison Lambert, MD MHS
Phone: 509-474-3821
?
mi
from
Spokane, WA
Click here to add this to my saved trials